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Abstract: Atopic dermatitis (AD), also known as eczema, is one of the most common chronic skin 
conditions worldwide, affecting up to 16% of children and 10% of adults. It is incurable and has 
significant psychosocial and economic impacts on the affected individuals. AD etiology has been 
linked to deficiencies in the skin barrier protein, filaggrin. In mammalian skin, l-histidine is rapidly 
incorporated into filaggrin. Subsequent filaggrin proteolysis releases l-histidine as an important 
natural moisturizing factor (NMF). In vitro studies were conducted to investigate the influence of 
l-histidine on filaggrin processing and barrier function in human skin-equivalent models. Our further 
aim was to examine the effects of daily oral l-histidine supplementation on disease severity in adult 
AD patients. We conducted a randomized, double-blind, placebo-controlled, crossover, nutritional 
supplementation pilot study to explore the effects of oral l-histidine in adult AD patients (n=24). 
In vitro studies demonstrated that l-histidine significantly increased both filaggrin formation and 
skin barrier function (P<0.01, respectively). Data from the clinical study indicated that once daily 
oral l-histidine significantly reduced (P<0.003) AD disease severity by 34% (physician assessment 
using the SCORingAD tool) and 39% (patient self-assessment using the Patient Oriented Eczema 
Measure tool) after 4 weeks of treatment. No improvement was noted with the placebo (P>0.32). 
The clinical effect of oral l-histidine in AD was similar to that of mid-potency topical corticoste-
roids and combined with its safety profile suggests that it may be a safe, nonsteroidal approach 
suitable for long-term use in skin conditions that are associated with filaggrin deficits such as AD. 
Keywords: atopic dermatitis, eczema, filaggrin, l-histidine, amino acid, skin barrier, nutritional 
supplement 
Introduction
Atopic dermatitis (AD) is a common, incurable, chronic inflammatory skin condi-
tion with a high prevalence in infants that causes considerable reduction in quality 
of life.1–4 Despite its prevalence and morbidity, few targeted therapies currently exist 
for AD. The mainstay of management being symptomatic relief based on the use of 
nonspecific anti-inflammatory topical steroids, calcineurin inhibitors, and systemic 
immunosuppressants such as azathioprine, cyclosporine, and prednisolone.4,5 These 
therapies are associated with adverse side effects, and there is a large unmet clinical 
need for the development of targeted AD therapies that are effective, economic, and 
safe for use, especially in younger children.5
A seminal report in 20066 demonstrated that of any marker so far identified, loss-
of-function mutations in the gene for the epidermal barrier protein profilaggrin (FLG) 
show the strongest association with AD.7,8 Profilaggrin, originally called “histidine-
rich protein” because of its very high (~10%) histidine content,9 is a large (>400 kDa) 
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 polypeptide synthesized in the epidermal granular layer. It 
accumulates in keratohyalin granules before dephosphoryla-
tion and processing, via lower weight intermediates, to ~37 
kDa filaggrin monomers.10,11 Filaggrin aggregates cytokera-
tins 1 and 10 and other intermediate filaments in the granu-
lar layer of keratinocytes, “collapsing” them as part of the 
epidermal terminal differentiation process to form corneo-
cytes and flattened squames that are critical for skin barrier 
function.12,13 Filaggrin is ultimately deiminated and cleaved 
by proteases, including kallikrein 5, caspase-14, elastase-2, 
matripase, and prostatin, into its component hygroscopic 
amino acids which are the major constituent of the “natural 
moisturizing factor” (NMF) which further contributes to 
barrier function through skin hydration and maintenance of 
stratum corneum acidity.14–16
Despite the genetic association between FLG mutations 
and AD being the strongest of any marker,6 the majority of 
AD individuals are wild type for FLG.17 In these individuals, 
epigenetic effects linked to disease severity and inflammatory 
cytokine milieu reduce filaggrin processing and NMF levels, 
thereby impairing skin hydration and barrier  integrity.18,19 
Abnormal proteolytic processing of profilaggrin into func-
tional filaggrin monomers due to protease–antiprotease 
imbalance may also play a role in the disease development in 
patients with wild-type FLG.20 A compromised skin barrier, 
whether due to FLG mutations or epigenetically compro-
mised profilaggrin processing, results in xerosis, allergen 
ingress, and AD disease initiation and exacerbation.21
Much of the current research activity is aimed at further 
understanding the involvement of filaggrin in the etiology 
of AD and translating these insights into new therapeutic 
approaches for this chronic and disabling condition.7,21 
Otsuka et al22 screened a 1120 compound library of bioactives 
and reported that JTC801, a four-aminoquinoline derivative, 
had the ability to increase FLG transcription and translation 
in a human skin-equivalent model. A gene therapy approach 
has been used to successfully deliver a filaggrin monomer 
coding construct into the FLG-deficient (flaky tail) mouse 
model, thus restoring a normal skin barrier phenotype.23
In this paper, we suggest that a simpler, nutritional supple-
mentation of l-histidine may have a beneficial potential in AD. 
l-histidine is a proteinogenic amino acid that is not synthe-
sized by mammals. In human infants, it is considered “essen-
tial” due to low levels of histidine-synthesizing gut microflora 
and minimal carnosinase activity, which helps in releasing 
free l-histidine from carnosine.24 Our interest in the use of 
 l-histidine in AD was stimulated by several  observations. 
Firstly, in both infants and adults, a histidine-deficient diet 
results in an eczematous rash.25 In rodents, 3H-histidine is 
rapidly (1–2 hours) incorporated into profilaggrin within 
keratohyalin granules after intraperitoneal or intradermal injec-
tion14,26 and within 1–7 days is released as a free NMF amino 
acid in the upper stratum corneum.14 Furthermore, reduced 
stratum corneum levels of free NMF amino acids, including 
histidine and its acidifying metabolite urocanic acid (UCA), 
are associated with AD disease severity and FLG genotype.27,28
Given this evidence for the dependence of filaggrin pro-
cessing and NMF formation on suitable levels of l-histidine, 
we hypothesized that l-histidine would both enhance filaggrin 
processing in an in vitro, organotypic, human skin model and 
have beneficial effects as a nutritional supplement in subjects 
with atopic dermatitis.
Methods
In vitro studies
Human keratinocyte culture condition
Immortalized human HaCaT keratinocytes29 of passages 
35–41 (gift from Dr J. Wood, University of Dundee;  origin – 
German Cancer Research Center (DKFZ), Heidelberg, 
 Germany) were seeded in six-well cell culture plates (Corning 
Incorporated, Corning, NY, USA) in D-MEM/F-12 medium 
with GlutaMAX (Thermo Fisher Scientific, Waltham, MA, 
USA) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin. Monolayer cultures were typically 
confluent after 48–72 hours. From days 15–21, culture media 
were supplemented with additional 1–5 mM of amino acids 
(l-lysine, l-histidine, or d-histidine; Sigma-Aldrich Co., 
St Louis, MO, USA). Cells were harvested and lysed with 
Laemmli buffer (Sigma-Aldrich Co.) on day 21.
sDs-Page and Western-blotting 
Total cellular protein from HaCaT monolayers was resolved 
by 9% sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) and Western blotting using standard 
protocols. Primary antibodies against the following antigens 
were used: filaggrin (goat polyclonal antibody; Santa Cruz 
Biotechnology Inc., Dallas, TX, USA) and keratin 10 (rab-
bit monoclonal; Abcam, Cambridge, UK). Densitometric 
analysis was performed with the VersaDoc Imaging System 
(Bio-Rad Laboratories Inc., Hercules, CA, USA); all bands 
were background-corrected and normalized to keratin 10. 
Organotypic skin-equivalent models and Lucifer 
Yellow penetration assay
Adult human dermal fibroblasts (HDFs; Thermo Fisher Sci-
entific) of passages 3–5 were mixed with rat tail Collagen 
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I (Thermo Fisher Scientific) and left to set in six-well cell 
culture plates. After 20–30 minutes, HaCaTs of passages 
35–41 were seeded on the apical aspect of the gels. Upon 
the HaCaT cells achieving confluency, the entire cultures 
(including the HDFs-containing collagen structures) were 
placed on plastic grids, creating an air–liquid interface with 
the apical aspect exposed to air. Skin-equivalent cultures were 
maintained for a total of 19 days and supplemented at days 
13–19 with 5 mM of either l-lysine, l-serine, or l-histidine 
(Sigma-Aldrich Co.). Samples were washed twice in PBS, 
fixed in formalin, embedded in paraffin, and sectioned. Stan-
dard protocols were used for hematoxylin and eosin staining. 
At day 19, the skin models exhibited keratin 10, involucrin, 
filaggrin, and loricrin (data not presented), particularly in the 
suprabasal layers, indicating epidermal-like differentiation.
For the penetration assay, 50 μL of 5 mM Lucifer Yel-
low CH dipotassium dye (Sigma-Aldrich Co.) was applied 
to the apical surface of each skin model in the center at 
5-minute intervals for a total of 10 minutes, before being 
washed off with PBS, fixed in formalin, and embedded in 
paraffin. Dewaxed and hydrated 3 μm transverse sections 
were visualized using fluorescence at 455–495/505–555 nm. 
Lucifer Yellow is a water-soluble fluorescent disulfonic acid 
anionic dye frequently used to study neuronal morphology. 
It has been used to assess the permeability barrier of mice 
and skin-equivalent models.30–33
Although our skin model did not show a well-established 
epidermal stratum corneum under hematoxylin and eosin 
staining, minimal dye penetration through the skin model 
was seen at 5 minutes, indicating a functional barrier, 
equating that of human epidermis. The dye penetration was 
not confluent throughout the entire sample. Therefore the 
average percentage dye penetration was calculated in three, 
 nonoverlapping, consecutive microscope fields on each 
section (a total of five sections were scored from each skin 
model).
Clinical nutritional supplementation pilot 
study
subjects
Adult (>18 years of age) subjects with a diagnosis of AD 
according to “The U.K. Working Party’s Diagnostic Criteria 
for Atopic Dermatitis” 34 were recruited. Exclusion criteria 
were pregnancy or lactation, liver disease, exposure to natural 
or artificial ultraviolet radiation, immunosuppression due to 
disease or medication, or use of Chinese herbal medicine in 
the 3 months preceding the study. Subjects were permitted to 
continue the use of nonmedicinal emollients and intermittent 
rescue therapy of topical steroid creams, which were recorded 
in the case report forms at each visit.
study design 
This was a randomized, double-blind, placebo-controlled, 
crossover, nutritional supplement pilot study that examined 
the effects of l-histidine in adult subjects with AD. Subjects 
were randomized using Research Randomizer (www.random-
izer.org) into either Group A or Group B. Initial AD disease 
severity was assessed by a trained dermatology research nurse 
using the validated SCORing Atopic Dermatitis (SCORAD) 
measure.35 The subjects were also trained to conduct the first 
of weekly self-assessments of their AD disease severity using 
the validated Patient Oriented Eczema Measure (POEM).35 
After a 2-week wash-out period in which subjects were asked 
not to use any medicinal product for their AD, the same 
measures were repeated and patients were provided with 
identical sachets containing either 4 g l-histidine (Group A) 
or 4 g placebo (erythritol); Group B) which was taken once 
a day, dissolved in a morning fruit drink. Patients returned 4 
and 8 weeks later and SCORAD was performed by a single, 
trained dermatology research nurse at each visit. Patients in 
Group A then crossed over to placebo and those in Group B 
took l-histidine for the next 8 weeks with SCORAD being 
performed by the trained dermatology research nurse at 
4-weekly intervals and POEM questionnaires being com-
pleted at weekly intervals.
regulatory and ethics approval
The UK Medicines and Healthcare Products Regulatory 
Agency confirmed that this nutritional supplementation pilot 
study on the effects of an amino acid was not classified as 
a “Clinical Trial of an Investigational Medicinal Product”. 
Bolton Research Ethics Committee gave permission for the 
study (#08/H1009/52) which was conducted in accordance 
with the Declaration of Helsinki 1964 and the EMEA Note for 
Guidance on Good Clinical Practice with written, informed 
consent obtained from all subjects.
statistics
Analysis of variance (one- or two-way, with Dunnett’s and 
Bonferroni post hoc tests performed, respectively) and simple 
linear regression analysis were used for the in-vitro studies. 
These were performed using GraphPad Prism version 4.00 
for Windows (GraphPad software, San Diego, CA, USA). 
Data are shown as mean values ± standard deviation.
Statistical analysis of the clinical pilot study was carried 
out by an independent statistical analyst (StatSol, Sereetz, 
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Germany) using SPSS version 15. The data are shown as 
mean ± standard errors and the significance of differences 
between means were expressed as a two-sided exact P-value 
of Wilcoxon rank-sum tests. In both the clinical and in vitro 
studies, P-values <0.05 were considered as significant.
Results
l-histidine effects on profilaggrin 
processing and skin barrier function  
in vitro
The addition of l-histidine to monolayer cultures of HaCaT 
keratinocytes (N=6) caused a decrease in a large 120 kDa 
profilaggrin intermediate11 and a concomitant increase in 
37 kDa filaggrin monomers (Figure 1). This increase in the 
37 kDa:120 kDa ratio (mean 1.69, SD 0.46) was l-histidine 
dose (0–5 mM) dependent (P<0.01) but was not seen 
when keratinocytes were incubated with 5 mM d-histidine 
(mean 0.68, SD 0.13) or l-lysine (mean 1.02, SD 0.37) 
(Figure 1). 
To examine the effect of l-histidine on epidermal barrier 
function, organotypic skin-equivalent cultures (Figure 2A) 
were incubated with 5 mM l-histidine (mean 3.60, SD 0.88) 
which led to a significant reduction in the penetration of 
Lucifer Yellow fluorescent dye (N=5, P<0.01) compared to 
the control (mean 7.67, SD 0.37). The same concentration 
of l-lysine (mean 8.78, SD 1.55) or l-serine (mean 7.64, 
SD 2.00) had no effect on the dye penetration (Figure 2B). 
Clinical nutritional supplementation pilot 
study
subjects’ demographics and aD severity
Twenty-four adults with AD were screened and randomized 
into two treatment groups. Patients in Group A received 
l-histidine in the treatment period 1 of 8 weeks, followed 
by placebo in treatment period 2, whilst patients in Group B 
received placebo followed by l-histidine (Figure 3A). Three 
patients (one in Group A and two in Group B) were lost to the 
study after the wash-out period (Figure 3B). The remaining 
patients entering the study had a mean (standard error of the 
mean [SEM]) age of 25.9 (1.6) years and 27.6 (1.6) years in 
Groups A and B, respectively; 55% of patients in Group A 
and 70% in Group B were females. The majority of patients 
Figure 1 L-histidine increases filaggrin protein formation in confluent human (HaCaT) keratinocyte monolayers. (A) Representative Western blots showing a decrease in 120 
kDa filaggrin and an increase in 37 kDa filaggrin formation after treatment with L-histidine. (B) L-lysine and D-histidine had no significant effect on filaggrin protein expression 
while L-histidine increased the 37 kDa to 120 kDa filaggrin ratio (P<0.01), as compared to controls. (C) L-histidine increased the 37 kDa:120 kDa filaggrin ratio in a dose-
dependent manner (R2=0.54, P<0.01). Error bars represent mean ± sD, where n=6. All bands were standardized to housekeeping protein keratin 10 loading control. **p<0.01.
Abbreviations: OD, optical density; WB, Western blot.
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Figure 2 L-histidine enhances the barrier function of organotypic skin model as indicated by penetration of Lucifer Yellow fluorescent dye. (A) A representative image of 
organotypic skin model with Lucifer Yellow dye seen under fluorescence and H&E staining. (B) Skin models grown in 5 mM L-histidine had reduced dye penetration (N=5; 
P<0.01), whereas L-lysine and L-serine had no effect on barrier function. 
Note: **p<0.01, n=5.
Abbreviation: H&E, hematoxylin and eosin.
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Figure 3 Clinical study protocol and patient details. (A) Schema showing the study protocol, (B) patients completed POEM questionnaires weekly, and (C) disposition of 
patients.There was a good correlation between SCORAD and POEM scores (R2=0.62) in study patients in Group A () (n=11) and Group B () (n=10) at week 0. There 
was no difference in mean SCORAD or POEM scores between the two groups (P=0.86). 
Abbreviations: POeM, Patient Oriented eczema Measure; sCOraD, sCOring atopic Dermatitis; WO, washout period.
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were Caucasians with one patient of Asian and one of Asian/
Caucasian race in Groups A and B, respectively.
Both clinician-scored SCORAD and patient-scored 
POEM were used as validated measures of AD disease 
severity.35 At week 0, there was no significant difference in 
the mean (SEM) SCORAD (31.9 [5.3] and 28.3 [3.6]) and 
POEM (18.4 [1.9] and 16.7 [6.2]) scores between Groups 
A (N=11) and B (N=10), respectively. Across all patients, 
there was a strong correlation between SCORAD and POEM 
scores at week 0 (R2=0.62) (Figure 3C). 
Effects of l-histidine nutritional supplementation on 
aD severity
Following l-histidine (period 1) supplementation, there was a 
significant reduction from week 0 scores in SCORAD (34%, 
P= 0.0029 and 32%, P=0.0029; Figure 4A) and POEM (39%, 
P=0.0020 and 39%, P=0.0010; Figure 4B) scores in Group 
A at weeks 4 and 8, respectively. No significant reduction 
in disease severity was seen in Group B which received 
placebo during period 1 at weeks 4 or 8 (SCORAD: –16%, 
P= 0.3223 and 6%, P=0.5391; POEM: 2%, P=0.8438 and 
16%, P=0.2695), respectively (Figure 4A and B). In period 
2, there was evidence that subjects in Group B, who crossed 
over from placebo to l-histidine, showed an improvement 
in their AD disease severity, although a carry-over effect of 
l-histidine in Group A over this period prevented meaningful 
analysis of study after the crossover. 
adverse events
Potential adverse events were monitored and recorded over 
the course of the study. There were no adverse events directly 
associated with administration of either l-histidine or the 
placebo. 
Discussion
Current AD therapy is based on the palliative use of 
emollients and anti-inflammatory agents such as topical 
corticosteroids or calcineurin inhibitors, with treatment of 
Figure 4 Effects of L-histidine nutritional supplementation on AD disease severity. (A) SCORAD and (B) POEM scores (mean ± SEM) were significantly reduced in Group A 
() patients at weeks 4 and 8 (SCORAD, P=0.0029 and P=0.0029; POeM, P=0.0020 and P=0.0010, respectively) in period 1, whilst the placebo had no effect in Group B () 
patients in period 1 (SCORAD, P=0.3223 and P=0.5391; POeM, P=0.8438 and P=0.2695, respectively). There is a clear “carry-over”effect of L-histidine in Group A between 
weeks 8 and 12, which precludes meaningful statistical analysis within the study period 2.
Abbreviations: AD, atopic dermatitis; POEM, Patient Oriented Eczema Measure; SCORAD, SCORing Atopic Dermatitis; SEM, standard error of the mean; WO, washout 
period.
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superinfection, particularly due to Staphylococcus aureus 
and Herpes simplex, when it arises. If topical management 
is unsuccessful, systemic treatment based on potent drugs 
such as corticosteroids, methotrexate, azathioprine, ciclo-
sporin A, or mycophenolate mofetil is needed. Well-known 
effects of long-term use of systemic corticosteroids include 
osteoporosis, cataracts, hypertension, and hyperglycemia. 
Immunosuppressants such as cyclosporin A and azathioprine 
also have serious potential side effects including hema-
tological abnormalities, predisposition to life-threatening 
infections, liver and renal failure, therefore requiring inten-
sive monitoring by the supervising doctor.5–36 Given the 
high prevalence of AD (up to 16% of children1 and 10% of 
adults2 worldwide), these adverse effects impose a consid-
erable burden on the individual patient and a high financial 
cost for health care systems and society. Clinical trials are 
currently being undertaken with biologic agents acting on 
elements of the immune system, but if effective, these will 
be expensive and are likely to be limited to the most severe 
and treatment-resistant AD. Concerns over the safety of this 
class of agents continue, particularly over increased infec-
tion risks and malignancy.5,36 A large unmet clinical need 
therefore remains for safe, convenient, targeted nonsteroidal 
interventions suitable for long-term use in the management 
of AD, particularly in children.
HaCaT monolayers grown in l-histidine-enriched media 
were associated with significantly increased expression of the 
37 kDa filaggrin monomers relative to the 120 kDa filaggrin 
intermediate. No increase in the expression of the filaggrin 
monomers was seen with media enriched with l-lysine and 
d-histidine, the structurally similar but biologically inactive 
isomers of l-histidine. The mechanism by which l-histidine 
enhanced filaggrin processing in an enantiomer-specific man-
ner is unclear, although l-histidine is a common participant 
in enzymatic reactions37 owing to the amphotericity of its 
imidazole side chain. 
The 37 kDa filaggrin monomers are intermediate prod-
ucts of filaggrin proteolysis which are further degraded into 
smaller filaggrin peptide fragments by proteases including 
calpain-1 and caspase-14 and finally into free amino acids 
by bleomycin hydrolase.38 Increased formation of the 37 
kDa filaggrin monomers by l-histidine would be expected 
to improve keratin aggregation and lead to increased levels 
of free amino acid NMF components. l-histidine is hygro-
scopic, and this ability to capture and retain water makes it an 
important component of the NMF.14 The ability of l-histidine 
to increase filaggrin processing with consequent enhance-
ment of skin barrier function is supported by our finding that 
skin equivalents grown in l-histidine-enriched media were 
more resistant to penetration by Lucifer Yellow fluorescent 
dye. The observed effect may be due to either improvement 
in keratin aggregation or increased level of NMF in the 
skin models due to increased substrate (i.e., more filaggrin 
monomers) availability for proteolytic degradation, or both. 
In individuals with wild-type FLG or heterozygous loss-of-
function FLG mutations, l-histidine may improve the disease 
symptoms by enhancing filaggrin formation and supplement 
NMF production, whilst in patients with homozygous FLG 
mutations, l-histidine may increase the amount of NMF in 
the skin. In all cases, enhancement of filaggrin formation 
and/or supplementing NMF would be expected to enhance 
skin barrier function and reduce the disease burden of AD. 
The use of primary human keratinocytes instead of 
HaCaT cells for the barrier function assay may be argued to be 
more “physiological”. However, our in-house skin-equivalent 
model is an adaptation of the technique demonstrated by 
Schoop et al,39 who have shown that HaCaT cells, cultured at 
an air–liquid interface on various matrixes serving as dermal 
equivalents, can be used to generate highly differentiated 
organotypic skin-equivalent structures in vitro. Unlike pri-
mary keratinocytes which are normally derived from human 
foreskin samples, the HaCaT cell line is of standardized 
quality as it is independent of donor variations.
The clinical nutritional supplementation pilot study 
suggests that oral l-histidine, administered once daily over 
a period of 4 weeks, is associated with improvement in the 
clinical signs and symptoms of adult AD patients. In both 
clinician-scored (SCORAD) and patient-scored (POEM) 
measures of disease severity, there was an ~40% decrease 
in AD activity over 4 weeks of treatment which is similar 
to that reported from using mid-potency (Group III) topi-
cal corticosteroids.40 The beneficial effects seen in Group A 
patients persisted for several weeks following crossover from 
l-histidine to the placebo suggesting a prolonged benefit of 
the l-histidine treatment. Importantly, no adverse events were 
reported that were attributable to l-histidine supplementation.
We have demonstrated, in vitro, a l-histidine-concen-
tration dependent increase in 37 kDa filaggrin monomer 
formation and l-histidine-associated improvement in the 
barrier function of a skin-equivalent model. This observation 
correlates with evidence from the clinical nutritional pilot 
study that oral l-histidine may have therapeutic benefits in 
AD. Although there are limitations relating to the sample 
size of our pilot study, if consistent, the results suggest that 
once-a- day oral l-histidine has similar effects in AD to those 
reported for mid-potency (Group III) topical corticosteroids.40
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These observations, when combined with its established 
safety profile, suggest that l-histidine nutritional supple-
mentation may be a safe, convenient, nonsteroidal interven-
tion suitable for long-term use in the management of AD, 
particularly in children. 
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